TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00123552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine+Artesunate
Description: Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine+Sulfadoxine/Pyrimethamine
Description: Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether+Lumefantrine
Description: Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
Study: NCT02946970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride
Description: Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intragastric administration of distilled water
Study: NCT04196608

Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria

Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria

Intervention type: DRUG
Intervention: imipenem- relebactam
Description: Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria

Intervention type: DRUG
Intervention: imipenem- relebactam
Description: Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
Study: NCT02580695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical-cord mesenchymal stromal cells
Description: Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
Study: NCT04471623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of DeTAP App and Home Devices
Description: DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
Study: NCT01749020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich Dark chocolate
Description: Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dark chocolate
Description: Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
Study: NCT00029172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Study: NCT04248985

Intervention type: OTHER
Intervention: Pre-Imaging - an ultrasound technique of acquiring images
Description: Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.

Intervention type: OTHER
Intervention: Pre-Imaging - an ultrasound technique of acquiring images
Description: Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
Study: NCT05084443

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drink
Description: Roselle and placebo drink for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink
Description: Roselle and placebo drink for 6 months
Study: NCT04014725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia Intelligent Diagnostic System
Description: An artificial intelligence to make diagnosis of myopia using ocular appearance images
Study: NCT03325920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABRUX
Description: All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABRUX
Description: All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
Study: NCT00336752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non operative treatment
Description: non operative treatment -casting for 6 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative treatment of ankle fractures
Description: operative treatment of ankle fractures
Study: NCT03940053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
Study: NCT03165929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: oral flurbiprofen spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: oral flurbiprofen spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo spray
Study: NCT04593316

Intervention type: OTHER
Intervention: Saliva collection
Description: A saliva sample will be collected before physical exercise.

Intervention type: OTHER
Intervention: Saliva collection
Description: A saliva sample will be collected before physical exercise.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.

Intervention type: OTHER
Intervention: Ingestible core temperature capsule intake
Description: The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.

Intervention type: OTHER
Intervention: Ingestible core temperature capsule intake
Description: The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.

Intervention type: OTHER
Intervention: Physical exercise
Description: The participant will perform a walk/run test.

Intervention type: OTHER
Intervention: Physical exercise
Description: The participant will perform a walk/run test.

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Heart rate will be monitored during physical exercise thanks to a chest belt.

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Heart rate will be monitored during physical exercise thanks to a chest belt.

Intervention type: OTHER
Intervention: Core temperature monitoring
Description: Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.

Intervention type: OTHER
Intervention: Core temperature monitoring
Description: Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
Study: NCT00553423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose 30 ml q6h for 48 hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 ml q6hrly for 48 hrs
Study: NCT05782686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Margin shaving
Description: In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Margin shaving
Description: In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
Study: NCT03103763

Intervention type: DRUG
Intervention: Warfarin
Description: Patients on warfarin for atrial fibrillation

Intervention type: DRUG
Intervention: Warfarin
Description: Patients on warfarin for atrial fibrillation
Study: NCT06587022

Intervention type: RADIATION
Intervention: Target volume delineation
Description: Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.

Intervention type: RADIATION
Intervention: Target volume delineation
Description: Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
Study: NCT03103763

Intervention type: DRUG
Intervention: Warfarin
Description: Patients on warfarin for atrial fibrillation
Study: NCT04317950

Intervention type: OTHER
Group type: OTHER
Intervention: Vojta
Description: Reflex locomotion stimulus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: sham stimulus
Study: NCT03181750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Intervention Group
Description: Bicultural, bilingual navigators conducting home visits with patients and caregivers.
Study: NCT01894061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-l00A
Description: NovoTTF-100A will be worn continuously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
Study: NCT00461838

Intervention type: PROCEDURE
Intervention: multidisciplinary laparoscopy
Description: Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
Study: NCT00717067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg tablet twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg capsule twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg tablet once daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg capsule twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg tablet once every 48 hours x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg capsule twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
Study: NCT03082742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study: NCT04610437

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthrodesis interphalangeal with intramedullary resorbable fixation system
Description: Interphalangeal arthrodesis of lesser toes with two different fixation systems.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis interphalangeal with intramedullary resorbable fixation system
Description: Interphalangeal arthrodesis of lesser toes with two different fixation systems.
Study: NCT04556461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: 2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
Study: NCT00606567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methods for monitoring patients with ICD's
Description: Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
Study: NCT00822172

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Levocarnitine tartrate
Description: Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cilostazol
Description: Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.
Study: NCT03111693

Intervention type: OTHER
Intervention: Unenhanced Coro-CT
Description: All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
Study: NCT04173637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AK101
Description: an anti-IL-12/23p40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02156128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed working memory training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study: NCT02179320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling
Description: Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture needle 0,25 x 40mm
Study: NCT03289897

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LiverMultiScan
Description: LiverMultiScan is an imaging technique which is able to identify early liver disease.
Study: NCT03439176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 1
Description: This strip contains a standard hydrocolloid adhesive found in ostomy devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 2
Description: This strip contains a standard hydrocolloid adhesive found in ostomy devices
Study: NCT06600893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity shockwave therapy (LiSWT)
Description: The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment
Study: NCT03439176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PL4
Description: This strip contains a new adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PL16-L
Description: This strip contains a new adhesive
Study: NCT06600893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity shockwave therapy (LiSWT)
Description: The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.
Study: NCT01400555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Study: NCT02237651

Intervention type: DEVICE
Intervention: topical anesthesia multi-use device

Intervention type: DEVICE
Intervention: topical anesthesia Intranasal Mucosal Atomization